Vaccine Peptide Derived from XAGE-1 to Prevent Tumor Growth
Description of Invention:
This invention describes a novel peptide derived from the protein XAGE-1 which is expressed specifically in cancer cells of prostate and breast cancer, as well as Ewing's sarcoma. This peptide is able to bind to human HLA-A2 molecules and to induce specific cytotoxic T lymphocyte response in vivo.
This peptide has therapeutic potential as an immunogen, and might induce cancer specific immune responses in cancer patients, which may cause regression of the cancer or prevent cancer metastasis.
Inventors:
Jay A. Berzofsky (NCI) Ira H. Pastan (NCI) and Masaki Terabe (NCI)
Patent Status:
DHHS Reference No. E-090-2003/0 --
U.S. Provisional Application No. 60/529,025 filed 12 Dec 2003
PCT Application No. PCT/US04/41639 filed 13 Dec 2004, which published as WO 2005/058944 on 30 Jun 2005
U.S. Patent Application No. 10/582,703 filed 12 Jun 2006
Portfolios: Cancer
Cancer -Therapeutics-Gene Therapy-Other Cancer -Therapeutics
For Additional Information Please Contact: David A. Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4632
Email: lambertsond@mail.nih.gov
Fax: (301) 402-0220
